色偷偷wwww88888,少妇熟女高潮流白浆,极品人妻VIDEOSSS人妻,九九热在线视频观看这里只有精品

Seragon Pharmaceuticals  
Seragon Pharmaceuticals 前身是Aragon的乳癌藥物開發(fā)部門

Seragon Pharmaceuticals’ orally active selective estrogen receptor degraders (SERDs) represent a potential new treatment for progressive metastatic breast cancer that may circumvent the problem of resistance to anti-hormonal therapies. SERDs are estrogen receptor antagonists that also induce a conformational change that results in the degradation of the receptor. Seragon has identified multiple SERDs that have pharmacokinetic profiles sufficient to drive a robust therapeutic response and result in degradation of the receptor and anti-tumor activity. The novel profile of these potent, orally bioavailable, nonsteroidal agents may result in greater efficacy and response rates in patients with hormone-refractory breast cancer compared to other drugs in development. Seragon’s most advanced leads induce tumor regressions in both tamoxifen sensitive and tamoxifen resistant tumor models in vivo. Based on these results and others, the company is currently advancing multiple, distinct lead SERD chemical scaffolds toward clinical development. Seragon’s SERDs are initially being developed for the treatment of women with late-stage, progressive metastatic disease.